Results 41 to 50 of about 5,352 (210)

Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals [PDF]

, 2021
Objectives Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and ...
Decosterd, Laurent A., Keiser, O., Stöckle, M., Aouri, Manel, Martinez de Tejada, B., Hösli, I., Marzolini, C., Haerry, D., Battegay, M., Vernazza, P., Rudin, C., Kahlert, C., Böni, J., Kovari, H., Nadal, D., Weber, R., Kouyos, R., Regenass, S., Dollenmaier, G., Egger, M., Schmid, P., Günthard, H., Martinetti, G., Guidi, Monia, Bucher, HC, Hasse, B., Yerly, S., Braun, DL, Gaspar, Frédéric, Barceló, Catalina, Nicca, D., Burton-Jeangros, C., Buclin, Thierry, Bernasconi, E., Calmy, A., Trkola, A., Cavassini, M., Kaiser, L., Aubert, V., Elzi, L., Gorgievski, M., Hirsch, HH, Csajka, Chantal, Rotger, Margalida, Fellay, J., Panchaud, Alice, Müller, N., Rauch, A., Ledergerber, B., Tarr, P., Pantaleo, G., Metzner, K., Furrer, H., Hoffmann, M., Fux, CA, Speck, R., Klimkait, T., Fehr, J., Cavassini, Matthias, Schöni-Affolter, F.   +59 more
core  

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Future Journal of Pharmaceutical Sciences, 2021
Background Tablet dosage forms containing combination of darunavir a protease inhibitor, cobicistat a cytochrome P450 3A inhibitor, emtricitabine and tenofovir alafenamide which were nucleoside reverse transcriptase inhibitors were approved by USFDA on ...
M. Satya Venkata Sakuntala, A. Lakshmana Rao, M. William Carey   +2 more
doaj   +1 more source

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +1 more source

Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials

Journal of Microbiology, Immunology and Infection, 2021
Despite aggressive efforts on containment measures for the coronavirus disease 2019 (COVID-19) pandemic around the world, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously spreading.
Chih-Cheng Lai, Chien-Ming Chao, Po-Ren Hsueh   +2 more
doaj   +1 more source

The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice

Scientific Reports, 2021
Schistosoma mansoni is less susceptible to the antiparasitic drug ivermectin than other helminths. By inhibiting the P-glycoprotein or cytochrome P450 3A in mice host or parasites in a murine model, we aimed at increasing the sensitivity of S. mansoni to
Belén Vicente, Julio López-Abán, Juliane Chaccour, Juan Hernández-Goenaga, Patricia Nicolas, Pedro Fernández-Soto, Antonio Muro, Carlos Chaccour   +7 more
doaj   +1 more source

Darunavir-Cobicistat versus Lopinavir-Ritonavir for COVID-19 Pneumonia: Qatar's Experience [PDF]

, 2022
Background: Coronavirus Disease 2019 (COVID-19) was first discovered in China and resulted in a pandemic crisis. 1,2 Many agents were investigated with inconclusive outcomes.
Elmekaty, Eman Zeyad I., Al Soub, Hussam, Al Maslamani, Muna, Abu Khattab, Mohammed, Hassanin, Rania, Al-Khal, Abdullatif, Rustom, Fatima, Eltaib, Sitelbanat, Alibrahim, Rim, Mohamed Ibrahim, Mohamed Izham, Elsayed, Ahmed   +10 more
core   +1 more source

Iatrogenic Cushing syndrome due to drug interaction between inhaled fluticasone and cobicistat [PDF]

, 2019
In this paper we report a case of iatrogenic Cushing syndrome due to a pharmacological interaction between fluticasone and cobicistat. Inhaled corticosteroids were previously thought to be safe, but increasing numbers of cases of iatrogenic Cushing ...
Monge, Elisa, Colombo, Valeria, Giacomelli, Andrea   +2 more
core   +2 more sources

Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring

British Journal of Clinical Pharmacology, EarlyView.
Lenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Aaron S. Devanathan, Thomas Glowa, Emily M. Thompson, Amanda J. Saylor, Thomas D. Nolin, Sharon A. Riddler, Ken S. Ho   +6 more
wiley   +1 more source

Lack of antiviral activity of darunavir against SARS-CoV-2

International Journal of Infectious Diseases, 2020
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are ...
Sandra De Meyer, Denisa Bojkova, Jindrich Cinatl, Ellen Van Damme, Christophe Buyck, Marnix Van Loock, Brian Woodfall, Sandra Ciesek   +7 more
doaj   +1 more source

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Pharmaceutics, 2023
Background: The clinical outcomes of antiretroviral drugs may be modified through drug interactions; thus, it is important to update the drug interactions in people living with HIV (PLHIV). Aim: To update clinically relevant drug interactions in PLHIV on
Pedro Amariles, Mónica Rivera-Cadavid, Mauricio Ceballos   +2 more
doaj   +1 more source